

4<sup>th</sup> February, 2022

To,  
The Manager,  
Dept. of Corporate Services,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001  
Scrip Code: 511509

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015-  
Advertisement in Newspapers-Reg.**

With reference to the subject cited above we are herewith enclosing the copies of advertisement issued in newspapers on 4<sup>th</sup> February, 2022 in “Financial Express” in English Language and in “Nav Telangana” in Telugu Language, with respect to publication of Un-Audited Consolidated Financial Results for the third quarter and nine months ended 31<sup>st</sup> December, 2021.

Kindly take the above information on record.

Thanking you,

Yours faithfully,

**For Vivo Bio Tech Limited**

A.Karthik  
A.Karthik  
Company Secretary



**CIRCLE SASTRA CENTRE LUCKNOW EAST**  
PNB, Opp RML Hospital, Vibhuti Khand Gomtinagar Lucknow 226010 Email: cs8271@pnb.co.in

Demand Notice u/s 13(2) of the Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002

All of you the under mentioned parties are hereby informed that the bank has initiated proceedings against each of you under the SARFAESI Act and the notice u/s 13(2) of the Act sent to each of you separately by registered & post dated below mentioned date but the notice was returned un-served/delivered. Hence each of you are hereby called upon to take notice to pay jointly and severally the outstanding amount, as detailed below, within 60 days from the date of this publication failing which bank will proceed against the above mentioned properties u/s 13(4) of the said Act. Needless to mention that this notice is addressed to you without prejudice to any other remedy available to the bank. The borrowers/guarantors in particular and public in general is hereby cautioned not to deal with the property mentioned below and any dealing with these properties will be subject to the charge of Punjab National Bank for the amounts and interest thereon:

| Name & Address of the Borrowers/Guarantors  | Description of the Mortgaged property(all the part & parcel of the property consisting of)                               | Dt. of Notice                  | Amount of notice (Rs.)  |
|---|--|--------------------------------|---|
| Borrower: Mr. Balaji Manufacturing, Prop. Ranjana Bajra, 289/183, Moti Nagar Near Agarkar College, Lucknow UP 226008<br>Khera No. 1979/4 Min bearing Municipal No. 555Ka/G-001 Ka Situated at Gangap Khera, Kanasui, Ward Kesari Khera, Lucknow, Boundaries: East- Plot of Seller (Sanjay Kalyal), West-25ft. Road, North-20ft. Road, South-Plot of Seller (Sanjay Kalyal). | Khera No. 1979/4 Min bearing Municipal No. 555Ka/G-001 Ka Situated at Gangap Khera, Kanasui, Ward Kesari Khera, Lucknow. | as on 31.03.2021<br>11.01.2022 | Rs. 24,27,254.00<br>Lacs Twenty Seven Thousand Two-Hundred Fifty four only with further int. and other charges, |

BO: eUBI Indira Nagar (149620) Lucknow  
You all are advised (1) To collect the original notice/cover addressed to you and if returned by postal authorities from the undersigned for more and complete details and (2) To pay the balance outstanding amount interest and costs etc, within 60 days from the date of notice referred to above to avoid further action under the SARFAESI Act.

Date: 04.02.2022, Place Lucknow

AUTHORISED OFFICER

### VIVO BIO TECH LIMITED

CIN: L65993TG1987PLC007163

Reg. Office: # 349/A, Pregnapur Village, Gajwel - 502311, Siddipet District, Telangana, India

Cell: 709 305 5580, E-mail: investors@vivobio.com / Website: www.vivobio.com

### EXTRACT OF UN-AUDITED CONSOLIDATED FINANCIAL RESULTS OF VIVO BIO TECH LIMITED FOR THE QUARTER AND NINE MONTHS ENDED 31<sup>ST</sup> DECEMBER, 2021

| Sl. No.     | Particulars  | Rs. In Lacs except per equity share data |                              |                      |
|-------------|--|--|------------------------------|----------------------|
|             |  | QTR ENDED 31.12.2021                     | NINE MONTHS ENDED 31.12.2021 | QTR ENDED 31.12.2020 |
| 1.          | Total Income from Operations   | 1292.02                                  | 3608.56                      | 1187.46              |
| 2.          | Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)   | 284.08                                   | 609.74                       | 290.13               |
| 3.          | Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)  | 284.08                                   | 609.74                       | 290.13               |
| 4.          | Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items# )  | 137.21                                   | 288.86                       | 222.76               |
| 5.          | Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] | 137.21                                   | 288.86                       | 222.76               |
| 6.          | Equity Share Capital   | 1420.45                                  | 1420.45                      | 1288.75              |
| 7.          | Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)   |  |                              |                      |
| i. Basic    | 0.97   | 2.03                                     | 1.73                         |                      |
| ii. Diluted | 0.93   | 1.95                                     | 1.70                         |                      |

Notes:  
1. The above Un-Audited Financial Results are reviewed and recommended by the Audit Committee were considered and approved by the Board of Directors at their meeting held on 2<sup>nd</sup> February, 2022.

2. The Consolidated Results include results of all subsidiaries.

3. The above is an Extract of the detailed format of Quarterly Un-Audited Financial Results filed with stock exchange under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the stock exchange website [www.bseindia.com](http://www.bseindia.com) and company's website [www.vivobio.com](http://www.vivobio.com)

4. Standalone Financial Information (Un-Audited)

| Sl. No. | Particulars           | Rs. In Lacs          |                              |                      |
|---------|-----------------------|----------------------|------------------------------|----------------------|
|         |                       | QTR ENDED 31.12.2021 | NINE MONTHS ENDED 31.12.2021 | QTR ENDED 31.12.2020 |
| 1.      | Total Income          | 1292.02              | 3608.56                      | 1,187.46             |
| 2.      | Profit before Tax     | 284.08               | 609.12                       | 290.13               |
| 3.      | Profit for the Period | 137.21               | 288.24                       | 225.29               |

For Vivo Bio Tech Limited

Sd/-  
M. Kalyan Ram  
Whole Time Director  
DIN: 02012580

Date: 2<sup>nd</sup> February, 2022

Place: Hyderabad

### Svantra Microfin Private Limited

Svantra

Regd. Office: Sunshine Tower, Level 20, Senapati Bapat Marg, Elphinstone Road, Mumbai - 400013.

Website: [www.svantramicrofin.com](http://www.svantramicrofin.com), Email: [secretarial@svantra.adityabirla.com](mailto:secretarial@svantra.adityabirla.com) CIN: U74120MH2012PTC227069

[Regulation 52 (B), read with Regulation 52 (A), of the SEBI (LODR) Regulations, 2015]

### Extract of Unaudited Financial Results for the quarter and nine months ended 31 December 2021

(Rs. In Lakhs except per share data)

| Sr. No. | Particulars  | Quarter ended 31/12/2021 | Nine Months Period ended 31/12/2021 | Year ended 31/03/2021 |
|---------|--|--------------------------|-------------------------------------|-----------------------|
|         |  | (Unaudited)              | (Unaudited)                         | (Audited)             |
| 1.      | Total Income from Operations   | 20,504.51                | 56,938.16                           | 55,684.85             |
| 2.      | Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)  | 1,329.32                 | 1,742.55                            | 3,684.43              |
| 3.      | Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)   | 1,329.32                 | 1,742.55                            | 3,684.43              |
| 4.      | Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)  | 917.83                   | 1,211.33                            | 2,708.12              |
| 5.      | Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)) | 920.50                   | 1,166.63                            | 2,699.13              |
| 6.      | Paid up Equity Share Capital   | 25,204.69                | 25,204.69                           | 25,204.69             |
| 7.      | Reserves (excluding Revaluation Reserve)   | 17,693.28                | 17,693.28                           | 6,492.56              |
| 8.      | Securities Premium Account   | 4.00                     | 4.00                                | 4.00                  |
| 9.      | Networth (including Compulsorily Convertible Non-Cumulative Preference Shares)   | 75,897.96                | 75,897.96                           | 57,197.25             |
| 10.     | Paid up Debt Capital / Outstanding Debt  | 395,171.41               | 395,171.41                          | 306,496.28            |
| 11.     | Outstanding Redeemable Preference Shares   | -                        | -                                   | -                     |
| 12.     | Debt Equity Ratio  | 5.21                     | 5.21                                | 5.36                  |
| 13.     | Earnings Per Share (of Rs. 10/- each)  |                          |                                     |                       |
| 1.      | Basic:   | 0.18                     | 0.24                                | 0.79                  |
| 2.      | Diluted:   | 0.18                     | 0.24                                | 0.79                  |
| 14.     | Capital Redemption Reserve   | NA                       | NA                                  | NA                    |
| 15.     | Debenture Redemption Reserve   | NA                       | NA                                  | NA                    |
| 16.     | Debt Service Coverage Ratio  | NA                       | NA                                  | NA                    |
| 17.     | Interest Service Coverage Ratio  | NA                       | NA                                  | NA                    |

Note:

a) The above is an extract of the detailed format of quarterly Financial Results filed with Bombay Stock Exchange (BSE) under Regulation 52 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly Financial Results are available on the website of BSE and on the Company's website ([www.svantramicrofin.com](http://www.svantramicrofin.com)).

b) For the other line items referred in regulation 52(A) of the LODR Regulation, pertinent disclosures have been made to the BSE and can be accessed on the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and on the Company's website ([www.svantramicrofin.com](http://www.svantramicrofin.com)).

c) As per the exemption given in the circular no. SEBI/HO/DDHS/CIR/2021/000000637 dated 5 October 2021 by Securities and Exchange Board of India (SEBI), the results for the corresponding quarter ended 31 December 2020 have not been provided.

By order of the Board  
For Svantra Microfin Private Limited  
Sd/-  
Ms. Ananyashree Birla (Director)  
DIN: 06625036

Place : Mumbai

Date: 04.02.2022

### NOTICE

### SBI MUTUAL FUND

A PARTNER FOR LIFE

### NOTICE CUM ADDENDUM TO THE SCHEME INFORMATION DOCUMENT / KEY INFORMATION MEMORANDUM OF SBI INTERNATIONAL ACCESS - US EQUITY FOF

Notice is hereby given that, pursuant to SEBI's communication dated January 28, 2022 and AMFI's communication dated January 30, 2022 regarding preventing of breach of industry-wide overseas limits as permitted by RBI, following provisions shall be applicable:

1. Subscriptions through lumpsum investment (including additional purchases/Switch in) and fresh registrations through Systematic Investment Plan (SIP)/Systematic Transfer Plan (STP)/Transfer of IDCW-ins in SBI International Access – US Equity FoF (the Scheme) will be discontinued with effect from February 4, 2022 i.e. post cut-off timing of February 3, 2022.
2. Existing systematic registrations like SIPs/STPs/Transfer of IDCW-ins etc. in the Scheme shall remain continue under the Scheme till further notice.
3. Investors are requested to note that the aforesaid suspension is not applicable for intra scheme switches between the Plan(s) and Options(s) in the Scheme.

The aforesaid provisions shall remain effective until the AMC issues a further notice in this regard.

All other terms and conditions of the Scheme remain unchanged. This addendum forms an integral part of the Scheme Information Document/Key Information Memorandum of the above Scheme as amended from time to time.

Investors are requested to kindly take note of the above.

For SBI Funds Management Limited

Sd/-  
Vinay M. Tonse

Managing Director & CEO

Place: Mumbai

Date: February 3, 2022

Asset Management Company: SBI Funds Management Limited (A Joint Venture between SBI & AMUNDI) (CIN: U65990MH1992PLC065289) Trustee: SBI Mutual Fund Trustee Company Pvt. Ltd. (CIN: U65991MH2003PTC138496) Sponsor: State Bank of India Regd Office: 9<sup>th</sup> Floor, Crescenzo, C – 38 & 39, G Block, Bandra-Kurla Complex, Bandra (E), Mumbai – 400051 Tel: 91-22-61793000 • Fax: 91-22-67425687 • E-mail: partnerforlife@sbfimf.com • www.sbfimf.com

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.

SBFIMF/2022/FEB/02

For All Advertisement Booking  
Call : 0120-6651214



( expleo )

Expleo Solutions Limited

CIN No:L64202TN1998PLC066604

Registered & Corporate office : 6A, Sixth Floor, Prince Infocity II, No. 283/3 &

